Assessing the Adverse Events of Patients with Advanced Renal Cell Carcinoma on Nivolumab Plus Cabozantinib Versus Sunitinib
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, detailed some of the AEs experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib.
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on the phase 3 CheckMate 9ER trial assessing nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During this discussion, Apolo detailed some of the adverse events (AEs) experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib during the phase 3 trial. Apolo also notes how the patients were able to handle the AEs they experienced during the trial.
